Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Active:	No
Cancer Type:	Colon/Rectal Cancer Unknown Primary	NCT ID:	NCT04793958
Trial Phases:	Phase III	Protocol IDs:	849-010 (primary) NCI-2021-03009 KRYSTAL-10
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Mirati Therapeutics
NCI Full Details:	http://clinicaltrials.gov/show/NCT04793958

Summary

Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the
efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the
second-line treatment setting in patients with CRC with KRAS G12C mutation.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.